Rajada dhabta ah ee daawaynta kansarka sida tallaalka mRNA Melanoma oo la tijaabiyay

 

Horumar la taaban karo, dhakhaatiirtu waxay bilaabeen tijaabooyin loogu talagalay tallaalka kansarka mRNA ee ugu horreeya adduunka ee loogu talagalay melanoma, nooca kansarka maqaarka ee mas'uulka ka ah ku dhawaad ​​​​132,000 dhimasho sannadkii.  Tallaalkan hal-abuurka leh, haddii lagu guuleysto, wuxuu calaamad u noqon karaa horumar la taaban karo oo laga gaaray la dagaallanka kansarka, taasoo u horseedi karta dawooyin joogto ah.

Dhaqan ahaan, qalliinku wuxuu ahaa daawaynta aasaasiga ah ee melanoma, oo leh shucaac, daawooyin, iyo kiimoterabi loo isticmaalo xaaladaha qaarkood.  Si kastaba ha ahaatee, khubarada ayaa hadda sahaminaya dariiqyo cusub, oo ay ku jiraan tallaalo si gaar ah loo dhisay oo loogu talagalay bukaan kasta.  Tallaaladani waxay farayaan jirka inuu beegsado oo uu burburiyo unugyada kansarka, si loo yareeyo khatarta cudurku inuu soo noqnoqdo.

Tijaabadii ugu dambaysay ee wejiga 2 ayaa muujisay natiijooyin rajo leh, taas oo muujinaysa hoos u dhac weyn oo ku yimid soo noqoshada kansarka ee bukaannada melanoma ee helay tallaallada gaarka ah.  Natiijooyinkan oo lagu dhiirrigeliyay, ayaa la billaabay tijaabada wejiga 3, oo ay hoggaaminayso Jaamacadda College London Hospitals NHS Foundation Trust (UCLH).

Dr. Heather Shaw, oo ah baadhaha isku xidhka heer qaran ee tijaabada, ayaa rajo ka muujisay suurtagalnimada tallaaladan si ay u daweeyaan melanoma iyo kansarrada kale, sida sambabada, kaadi haysta, iyo kansarka kelyaha.

"Tani waa mid ka mid ah waxyaabihii ugu xiisaha badnaa ee aan aragnay muddo dheer," ayuu yiri Dr. Shaw.  "Tani waa qalab runtii si fiican loo sharfay.  Bukaanku runtii aad bay ugu faraxsan yihiin iyaga."

Tallaalka, oo loo yaqaan mRNA-4157 (V940), waa nooc ka mid ah daawaynta neoantigen ee shakhsi ahaaneed.  Waxaa loogu talagalay in lagu kiciyo habka difaaca si loo aqoonsado oo loo weeraro unugyada kansarka gaarka ah ee ku jira buro kasta oo bukaan ah.

Si loo shakhsiyeeyo tallaalka, muunad buro ah ayaa la ururiyaa inta lagu jiro qalitaanka, oo ay ku xigto taxanaha DNA iyo isticmaalka sirdoonka macmal.  Habkani waxa uu keenayaa tallaal ka hortagga kansarka oo si gaar ah loo qaabeeyey kaas oo ku habboon buro bukaanka.

"Tani aad bay u badan tahay daawaynta shakhsi ahaaneed waxayna aad uga xariifsan tahay dareenka qaar marka loo eego tallaalka," ayuu yiri Dr. Shaw.  "Gabi ahaanba waa loo dhisay bukaan-socodka - ma siin kartid kan bukaanka xiga ee khadka sababtoo ah ma filaysid inuu shaqeeyo."

Tijaabada wejiga 3 waxa ay rabta in ay qorto ku dhawaad ​​1,100 bukaan oo caalami ah, oo ay ku jiraan 60 ilaa 70 bukaan oo ka socda UK.  Garabka UK ee tijaabada ayaa lagu qaban doonaa guud ahaan siddeed xarumood, oo ay ku jiraan goobaha London, Manchester, Edinburgh, iyo Leeds.

Steve Young, 52, oo ka yimid Stevenage ee Hertfordshire, waa mid ka mid ah bukaannadii ugu horreeyay ee ka qaybqaata tijaabada UCLH.  "Runtii, runtii aad ayaan u faraxsanahay," ayuu yidhi.  "Tani waa fursaddayda ugu fiican ee aan ku joojin karo kansarka jidkiisa."

Hadafka ugu dambeeya ee cilmi-baaristan cusub waa in la helo dawo joogto ah bukaannada kansarka.  Dr. Shaw waxa uu rajo ka muujiyay in tallaalladan la shakhsiyeeyay ay noqon karaan beddelka ciyaarta tallaalka difaaca jirka, iyaga oo rajo cusub siinaya bukaannada qaba melanoma sare iyo kansarrada kale.